ROCHESTER, N.Y., Aug. 10 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that it has opened an office in central Europe to focus on its growing portfolio of international customers. The office will initially be staffed by a senior project manager who joins the company with an extensive background in global clinical trial management with leading pharmaceutical companies. This is the company's second European location joining the UK office which opened in 2008.
"As a global company, we are very excited to expand our presence with this office in central Europe," said Chief Executive Officer Jeff Markin. He continued, "With a thriving international customer base it is vital that we provide dedicated services to better meet the needs of our clients. Combined with our UK office, we are now able to offer devoted business development, site management, and project management services to our international customers."
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.
CONTACTS: |
||
Investor Relations: |
||
Tim Ryan |
||
The Shoreham Group LLC |
||
80 Eighth Ave, Ste 1107 |
||
New York, NY 10011 |
||
+1 212 242 7777 Direct |
||
+1 646 342 6199 Cell |
||
+1 484 377 9916 Fax |
||
Company: |
||
Molly Henderson |
||
Chief Business and Financial Officer, Sr. Vice President |
||
VirtualScopics, Inc. |
||
500 Linden Oaks |
||
Rochester, New York 14625 |
||
+1 585 249 6231 Phone |
||
+1 585 218 7350 Fax |
||
SOURCE VirtualScopics, Inc.
Share this article